Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Excedrin sales up 10% to $55 mil. in third quarter; Boost sales are $19 mil..

This article was originally published in The Tan Sheet

Executive Summary

BRISTOL-MYERS EXCEDRIN SALES UP 10% TO $55 MIL. IN THIRD QUARTER, helping the company's consumer products revenues rise 4% during the three-month period, Bristol-Myers Squibb reported Oct. 21. Consumer products revenues rose 11% excluding the negative effect of foreign currency translations versus the strong dollar, the company said. Excedrin received a recommendation for approval as an OTC treatment for migraine by an FDA advisory committee in July, the company noted. The product line also likely continues to benefit from the recommendations for low-dose aspirin use in the primary and secondary prevention of cardiovascular disease.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087690

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel